Almirall's psoriasis drug drives 2021 growth ahead of duller 2022 outlook
Dermatology group Almirall’s 2021 growth was partially due to strong sales of psoriasis drug Ilumetri, which grew by 87 percent. With the recently announced European rollout of psoriasis cream Wynzora, developed by Danish MC2 Therapeutics, Almirall predicts a good start to 2022, although both growth and profits are expected to slow down.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
On Monday, Spanish dermatology group Almirall has released its full-year report for 2021. The headliner has been sales of psoriasis drug Ilumetri, an anti-IL-23 monoclonal antibody treatments for adults that was launched around a year ago. Ilumetri sales reached EUR 82m in 2021, corresponding to a growth of 87 percent, according to the report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Chairman intends to retire from Almirall in May
For subscribers
